In this session the do’s and don’ts of withdrawal of Nucleos(t)ide Analogues will be discussed. In a selected group of patients NA withdrawal appears to be effective in invigorating the immune system leading to HBsAg loss. On the other hand treatment with

In this session the progress of treatment development in order to functionally cure hepatitis B will be discussed. Both antiviral and immunological target engagement is currently applied. Although we are able to decrease HBsAg levels substantially and eve

The COVID pandemic has dramatically accelerated an existing decline in the number of healthcare workers due to population shifts, among other trends. This is in striking contrast to the increased burden of chronic liver diseases on healthcare systems and

With the approval of new medications for obesity, one of the question that comes up in liver clinic is who should be prescribing these medications. Although multidisciplinary clinics are ideal, it is not pragmatic in most institutions.  Liver clinics may

This MTE session will focus on implementing hepatitis C virus screening and linkage to care during pregnancy. Topics will include partnering with ob/gyn to provide hepatitis C screening, approaches to counseling and treatment of pregnant people with hepat

The aim is to discuss metabolic alterations that are involved in liver fibrosis and portal hypertension.

This session will focus on how Northwestern built a liver transplant program that sought to mitigate disparities for Hispanic and Black patients.

Frailty is a predictor of worse outcome in patients with cirrhosis.  This program will discuss the assessment of frailty in the outpatient setting.

What is the future of microbiome research in autoimmune liver disease? In this session, we’ll review the role of the microbiome in autoimmune disease progression and outcomes and share what might be next in gut health research. We’ll also review a few of

MTE to understand the best strategies for surveillance and management of hepatobiliary cancers in patients with  PSC particularly cholangiocarcinoma